Sanofi - ADR (SNY) News

Sanofi - ADR (SNY): $53.42

-0.50 (-0.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SNY News Items

SNY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SNY News Highlights

  • 500 - Internal server error
  • Over the past 25 days, the trend for SNY's stories per day has been choppy and unclear. It has oscillated between 1 and 30.
  • The most mentioned tickers in articles about SNY are SA, GSK and REGN.

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection

Sanofi SA’s (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia without a recent history of blood transfusion. Topline results will be presented at the European Hematology Association 2021 Congress. The results of the 42-subject study showed that sutimlimab was able to reduce the destruction of red blood cells (haemolysis) seen in patients with CAD within one week of

Yahoo | June 11, 2021

New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia

New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningfulFindings provide further evidence that sutimlimab results in rapid inhibition of C1-activ

Yahoo | June 11, 2021

The next generation Covid-19 vaccines seeking a slice of the market

BioNTech/Pfizer and Moderna, the pandemic’s mRNA-based vaccine frontrunners, have already booked billions of dollars in revenue, which they are using to boost production, sign new contracts and entrench their positions. Likewise, Oxford/AstraZeneca and Johnson & Johnson have been rolling out their cheaper and easier to transport shots for months, while Chinese and Russian-made vaccines dominate in several markets. Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs.

Yahoo | June 11, 2021

Sanofi SA (SNY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Sanofi SA (SNY) Goldman Sachs 42nd Annual Global Healthcare Conference June 9, 2021 2:10 PM ET Company Participants John Reed - EVP, Global Head of Research & Development Conference Call Participants Keyur Parekh - Goldman Sachs Presentation Keyur Parekh Good morning, good afternoon and good evening, and thank you all...

SA Transcripts on Seeking Alpha | June 9, 2021

U.S. response to COVID-19 has a greater list of failures than accomplishments: Expert

Chris Meekins,Raymond James Healthcare Policy Analyst, joins Yahoo Finance Live to break down what went well and poorly during the COVID-19 pandemic and how to better prepare for possible future pandemic.

Yahoo | June 8, 2021

Translate Bio gets $50M mRNA vaccine program milestone payment from Sanofi Pasteur

Translate Bio (TBIO) announces that it has received a $50M milestone payment from Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), under the collaboration related to its influenza mRNA vaccine program.The payment was triggered following the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur’s Phase 1...

Seeking Alpha | June 7, 2021

Elevation Oncology Files for $100M IPO

Elevation Oncology has filed to raise $100 million in an IPO. See SEC prospectus here. Proceeds will be used to support the development of seribantumab that failed multiple trials at Merrimack Pharmaceuticals Inc (NASDAQ: MACK) before being picked up by Elevation and repositioned as a treatment for solid tumors harboring an NRG1 fusion. The anti-HER3 antibody failed multiple mid-phase trials, causing Sanofi SA (NASDAQ: SNY) to return the rights to the drug and ultimately leading to Merrimack off

Yahoo | June 7, 2021

Sanofi launches its new global employee share ownership plan

Sanofi launches its new global employee share ownership plan PARIS - June 7, 2021 - Sanofi today launches Action 2021, its global employee share ownership plan, open to 92,000 employees in 73 countries. The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company. "The record level of employee participation in last

Yahoo | June 7, 2021

Jefferies Stick to Their Buy Rating for Sanofi By Investing.com

Jefferies Stick to Their Buy Rating for Sanofi

Investing.com | June 5, 2021

Sanofi (SNY) Presents At 2021 American Society of Clinical Oncology Annual Meeting - Slideshow

The following slide deck was published by Sanofi in conjunction with this event....

SA Transcripts on Seeking Alpha | June 4, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8022 seconds.